Exenatide, an exogenous GLP-1 analogue, was found to be more beneficial than the other current regimens (DPP-4 inhibitors, insulin or tiazolidinediones), in reaching therapeutic goals recommended by the American Diabetes Association in the treatment of T2DM, which is also promising in the reduction of other co-morbidities such as cardiovascular risk [50]. This evidence concerns the gene DPP4 and diabetes mellitus.